drugset

drugset / Trial / NCT00111306

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00111306 ↗

Phase 3 Terminated 510 enrolled UCB Pharma

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.

Timeline

Start: 2005-06
Primary completion: 2007-03
Completion: 2007-03

Publications

Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Epratuzumab	Monoclonal antibody	—	—

Indications